X-Ray Crystal Structure of HLA-DR4 (DRA*0101, DRB1*0401) Complexed with a Peptide from Human Collagen II  by Dessen, Andréa et al.
Immunity, Vol. 7, 473±481, October, 1997, Copyright 1997 by Cell Press
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(DRA*0101, DRB1*0401) Complexed
with a Peptide from Human Collagen II
genes possess a ªshared epitopeº formed by very simi-
lar amino acids at positions 67±74 (Table 1) (Gregersen
et al., 1987; Nepom et al., 1989; Hiraiwa et al., 1990),
now known to form part of the a helix at one edge of
the peptide-binding site of DR molecules (Brown et al.,
AndreÂ a Dessen,* C. Martin Lawrence,* Susan Cupo,§
Dennis M. Zaller,§ and Don C. Wiley*²³‖
*Laboratory of Molecular Medicine
²Howard Hughes Medical Institute
The Children's Hospital
1993). The majority of RA patients in the groups that doBoston, Massachusetts 02115
not carry the HLA-DR4 subtype (e.g., specific ethnic³Department of Molecular and Cellular Biology
groups), although they carry alleles with amino acidHarvard University
variation in the peptide-binding site, share identical resi-Cambridge, Massachusetts 02138
dues with the DRB1*0401 sequence at the shared epi-§Molecular Immunology
tope (Nepom et al., 1989; Nepom and Erlich, 1991). Site-Merck Research Laboratories
directed mutagenesis experiments of the 67±74 DR4bRahway, New Jersey 07065
region (Hiraiwa et al., 1990; Fu et al., 1995; Signorelli et
al., 1995) as well as studies of spontaneous mutants in
mice (Mengle-Gaw et al., 1984) indicate that sequence
Summary differences in this region, especially in residue b71, can
profoundly influence T cell recognition and immune re-
Genetic predisposition to rheumatoid arthritis (RA) is sponse.
linked to the MHC class II allele HLA-DR4. The charge The shared epitope residues are critical in selecting
of the amino acid at DRb71 in the peptide-binding site specific amino acids at position 4 (P4) of peptides that
appears to be critical in discriminating DR molecules will bind to DR4. In particular, among peptides with
linked to increased disease susceptibility. We have electrostatically charged residues at P4, only those with
determined the 2.5 AÊ x-ray structure of the DR4 mole- negatively charged residues (Asp and Glu) at this posi-
cule with the strongest linkage to RA (DRB1*0401) tion bind to DR molecules with associated increased
complexed with a human collagen II peptide. Details susceptibility to RA; peptides with such residues do not
of a predicted salt bridge between lysine DRb71 and bind to molecules such as DRB1*0402, an allotype that
aspartic acid at the P4 peptide position suggest how differs in sequence only at the shared epitope and that
it may participate in both antigen binding and TCR is not associated with increased susceptibility to the
activation. A model is proposed for the DR4 recogni- disease (Table 1) (Hammer et al., 1995; Woulfe et al.,
tion of collagen II (261±273), an antigen immunodomi- 1995; Wucherpfennig and Strominger, 1995). The se-
nant in human-transgenic mouse models of RA. quence differences between DRB1*0401 and DRB1*0402
change the electrostatic charge in the pocket that binds
the P4 side chain of peptides. Residue DRb71 is posi-Introduction
tively charged (Lys or Arg) in DRB1*0401 and other RA-
associated allotypes and is negatively charged in theIncreased susceptibility in humans to specific autoim-
nonassociated DRB1*0402 (Table 1). This suggests thatmune diseases has a strong genetic association with
the mechanism by which specific DR molecules are as-specific class I and class II alleles of the major histocom-
sociated with RA could involve their selectivity for bind-patibility complex (MHC) (reviewed by Tiwari and Tera-
ing a peptide with a negatively charged P4 (Hammer etsaki, 1985; Todd et al., 1988; Wucherpfennig and Strom-
al., 1995; Wucherpfennig and Strominger, 1995). Suchinger, 1995). Genetic predisposition to rheumatoid
peptide selectivity may alter the T cell repertoire duringarthritis (RA) has been strongly associated with the MHC
T cell differentiation in the thymus or selectively activateclass II HLA-DRB1 locus (Nepom et al., 1989; Lanchbury
arthritogenic T cells at the level of antigen presentation,et al., 1991; Nepom and Erlich, 1991). Approximately
leading to the development of autoimmunity (Gregersen80% of Caucasian patients with RA express DR4 (DRB1*
et al., 1987). An alternative hypothesisÐthat the se-0401, DRB1*0404) or DR1 (DRB1*0101) allotypes (Feld-
quences of the shared epitope are themselves presentedman et al., 1996). DRB1*0401 confers higher risk than
as a peptide by another MHC moleculeÐcannot be ruledany other allele; it is carried by 50% of all patients testing
out (Zanelli et al., 1995, 1996).positive for rheumatoid factor (Gregersen et al., 1987;
The antigen(s) responsible for the induction of theNepom and Erlich, 1991). Of patients with a particularly
autoimmunity in RA are unknown. Type II collagen (CII)severe form of arthritis (Felty's syndrome), 92%±95%
is a candidate antigen since it is thepredominant proteinexpress the HLA-DR4 molecule, with increased disease
of joint cartilage and since auto-antibodies against CIIfrequency mainly due to the presence of DRB1*0401
are found in elevated levels in the serum and joints of(Lanchbury et al., 1991). The presence of DR4 is also
patients with RA (Banerjee et al., 1988). If CII is not thelinked to increased duration of chronic arthritis in pa-
antigen that induces RA in humans, it seems that it istients with Lyme disease (Steere et al., 1990).
involved in at least part of the autoimmune reactionThe DRb chains encoded by the RA-related DRB1
that results in joint inflammation. In a number of rodent
models, RA can be induced by immunization with CII
(Fugger et al., 1994; Khare et al., 1995; Rosloniec et al.,‖ To whom correspondence should be addressed (e-mail: wiley@
xtal0.harvard.edu). 1997). A set of eight peptides that bind selectively to
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Table 1. Amino Acids in the Shared Epitope
67 70 71 74 RA Association
DRB1*0401 Leu Gln Lys1 Ala 11
DRB1*0404 Ð Ð Arg1 Ð 11
DRB1*0101 Ð Ð Arg1 Ð 11
DRB1*0402 Ile Asp2 Glu2 Ð None
DR molecules associated with RA, when compared to
DR molecules not associated with RA, were identified
from four candidate antigens in the pathogenesis of
arthritis (Hammer et al., 1995). Two of these peptides
were from collagen II: CII(1168±1180) and CII(1350±
1362). These observations suggested that a structural
study of DR4 complexed with a CII peptide could provide
insight into the shared epitope and the mechanism of
the MHC association with the development of RA.
We have determined the x-ray crystal structure of
the HLA-DR4 allotype DRB1*0401, which confers the
greatest susceptibility to RA, complexed to the CII(1168±
1180) peptide (Hammer et al., 1995). The crystal also
contains Staphylococcus aureus enterotoxin B (SEB),
which promoted the growth of ordered crystals. The
structure, refined to 2.5 AÊ resolution, reveals that the
peptide conformation is extremely similar to that ob-
served in other MHC class II/peptide complexes (Brown
et al., 1993; Jardetzky et al., 1994; Stern et al., 1994a;
Stern and Wiley, 1994b; Ghosh et al., 1995; Fremont et
Figure 1. Ribbon Diagram of the HLA-DR4/CII(1168±1180)/SEBal., 1996; Jardetzky et al., 1996). For the first time, no
Complexdimer of dimers was observed in an MHC class II crystal.
Peptide atoms are shown as balls and sticks. Two loops from SEBIn this article we also discuss the structural basis for
that are not visible in electron density maps are represented by
the selective binding of peptides to DRB1*0401 and dotted lines.
propose a model for bound CII peptide (261±273), the
immunodominant peptide in human±transgenic mouse
1) and the last residue of the peptide, for which themodels of RA (Fugger et al., 1996; Rosloniec et al., 1997).
electron density is weak, suggesting that it is disordered
(Figure 2).
Results and Discussion
The Structure of the DR4/Collagen Peptide/SEB
Complex Resembles Other MHC Class II/PeptideThe Superantigen SEB Facilitated Growth of
DR4/Peptide Crystals Ordered Well Enough and MHC class II/Peptide/Superantigen Complexes
The overall structure of the SEB/DR4 complex is veryfor Structure Determination
by X-Ray Crystallography similar to that of SEB/DR1, since DR1 and DR4 share
the same a chain, to which SEB binds (Jardetzky et al.,Although small crystals of HLA-DR4 (DRA*0101, DRB1*
0401) complexedwith the type II collagen peptide (1168± 1994). However, no dimer of ab dimers is observed in
the SEB/DR4 crystal (compare Figure 1 to Figure 1D1180) could be grown from DR4 expressed in insect
cells and although crystals of DR4 diffracting to 3.7AÊ in Jardetzky et al., 1994). The bound collagen peptide
(QYMRADQAAGGLR; M 5 P1) is extended in a polypro-resolution have been grown from DR4 purified from hu-
man lymphoblastoid cells (Gorga et al., 1991), it was line type II conformation (Stern et al., 1994a; Ghosh et
al., 1995; Jardetzky et al., 1996) with the Met-1170, P1,necessary to add the superantigen SEB to DR4/CII
(1168±1180) to grow crystals suitable for high-resolution occupying the major nonpolar pocket, first identified in
DR1 (Brown et al., 1993; Stern et al., 1994a) (Figure 3A).(2.5AÊ ) structural studies. The addition of SEB has also
been used by Stallings and colleagues to grow DR4 As in other class II MHC/peptide structures, peptide
side chains at P1, P4, P6, and P7 project into pocketscrystals complexed with an influenza virus HA peptide
(Stallings et al., 1996, Acta Crystallogr., abstract). The in the peptide-binding groove (P9, which usually fits in
a pocket is Gly, with no side chain in CII(1168±1180))structure of DR4/CII(1168±1180)/SEB was determined
by molecular replacement using coordinates from the (Figure 3A). The arginine at P2 hydrogen-bonds to the
carbonyl oxygen of b chain Thr-77.DR1/SEB complex (Jardetzky et al., 1994) as a search
model, from which the 16 residues differing between There are 11 hydrogen bonds between main-chain
peptide atoms and DR4, forming a network of hydrogenDR1 and DR4 were substituted by Ala (see Experimental
Procedures). The final model includes all but 19 residues bonds to conserved class II residues that has been
found in all class II MHC/peptide complexes to datefrom two disordered loops of SEB (dotted lines in Figure
Structure of an HLA-DR4/Collagen Peptide Complex
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Figure 2. CII(1168±1180) Peptide in the HLA-DR4 Binding Site Overlaid with an Fo-Fc Omit Map Contoured at 2.2 s
Collagen peptide atoms were omitted from electron density map calculation. Gln at P 22, Gln at P5, and Leu at P10 were modeled as Ala.
(Stern et al., 1994a; Stern and Wiley, 1994b; Ghosh et solvent exposed and appears to be partly disordered
beyond the Gly at P9 in this crystal. Two peptide resi-al., 1995; Fremont et al., 1996; Jardetzky et al., 1996)
(Figure 3B). Two hydrogen bonds to the peptide main dues N-terminal to the P1 Met, the Tyr at P 21 and
the backbone atoms for Gln at P 22, are well orderedchain at P10, formed by Asp-b57 and Arg-a76 in class
II MHC molecule binding clefts, are not observed in (Figures 2 and 3A).
In the DR4/SEB crystal lattice, a second extensiveDR4/CII(1168±1180) because the peptide C-terminus is
interaction is observed between DR4 and SEB, in addi-
tion to that described in the DR1/SEB complex (Jardet-
zky et al., 1994). It is almost certainly not physiological,
because the two class II molecules are oriented almost
perpendicular to each other, an arrangement that would
not be expected to occur on the cellular membrane.
This interaction involves pairing of two b-strands in the
C-terminal portion of SEB (residues 129±149) and a
b-strand involving residues 179±189 of the HLA-DR4
b-domain, to form an intermolecular b sheet. These con-
tacts appear to stabilize SEB in the DR4/SEB crystal
lattice, allowing regions that appeared disordered in the
DR1/SEB crystal to be defined here (see Experimental
Procedures).
The Interactions between the CII Peptide Side
Chains and DR4 Match Motifs Derived from
Phage-Display and Peptide Libraries
Peptides that bind to DRB1*0401 show amino acid pref-
erences at six positions: P1, P2, P3, P4, P6, and P7.
The sequence motif deduced from phage-display and
synthetic peptide libraries for DRB1*0401 is: P1 large
nonpolar, P2 Arg, P3small nonpolar (Ala, Gly), P4 nonpo-
lar, P6 Thr/Ser, and P7 aliphatic (Hammer et al., 1993,
1994, 1995). The CII(1169±1180)/DR4 complex shows
the basis for these preferences.
The DR4 pocket that binds P1 Met (peptide residue
1170) is deep and nonpolar (Figure 3A). A Gly/Val dimor-
phism at DRb86 in this pocket influences side chain
Figure 3. CII(1168±1180) Peptide in the HLA-DR4 Binding Site specificity at P1 (Busch et al., 1991; Demotz et al., 1993;
Newton-Nash and Eckels, 1993; Verreck et al., 1993).(A) CII(1168±1180) peptide in the HLA-DR4 binding site. P1 Met
(green) fits into a deep pocket. Asp P4 and Lys-b71 interact in pocket Glycine b86 as visualized here in DRB1*0401 and earlier
4. P-2, P5, and P10 are displayed as Ala. in DR1 (Brown et al., 1993; Stern et al., 1994a; Jardetzky
(B) Hydrogen bonds between CII(1168±1180) and HLA-DR4. Peptide et al., 1996) allows the binding of large aromatic and
side chains are shown as Ala, with the exception of Asp P4. Ten
nonpolar side chains, while Val as in DRB1*0402 andhydrogen bonds are made from the peptide mainchain to conserved
DRB1*0404 and visualized in DR3 (Ghosh et al., 1995)class II residues. Lys-b71 makes two other hydrogen bonds, one
to the P4 Asp side chain and another to the carbonyl of P5. decreases the size of the pocket, excluding aromatic
Immunity
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Figure 4. Interactions in the P4 Pockets of HLA-DR1, HLA-DR4 (DRB1*0401), and HLA-DR4 (DRB1*0402)
(A) Interatomic contacts in the P4 pocket of DR4/CII(1168±1180). Six hydrogen bonds are found in the pocket, including the one to a bound
water molecule. Other residues forming the shared epitope are shown in yellow.
(B) Pocket 4 of the DR1/HA complex.
(C) Hypothetical model of pocket 4 of DRB1*0402, an HLA-DR4 allele that is not associated with the development of arthritis.
side chains. Substitutions at DRb86 in DRB1*0401 mark- of the a helix in the b domain, points directly into the
peptide-binding site. Phage-display and peptide libraryedly affect T cell recognition, probably by altering the
peptide-binding characteristics of the molecule via its studies revealed an increased frequency of nonpolar
residues at P4 (Met, Ala, Val, and Leu) (Hammer et al.,P1 pocket (Barber et al., 1991; Fu et al., 1995). Within
DR4 subtypes, the DRb86 dimorphism determines the 1993), but charged residues binding in this pocket have
been implicated in autoimmune diseases (Hammer etP1 specificity but is not critical in the linkage to RA,
since both residues occur in RA-associated and -nonas- al., 1995; Wucherpfennig and Strominger, 1995) (see
next section).sociated molecules (Hammer et al., 1995).
The side chain of P2 Arg extends across the binding The glutamine side chain of P5 projects up and out
of the peptide-binding site. Electron density for the sidecleft, so that it can be recognized by a T cell receptor
(TCR), and its positively charged guanidinium group chain is broken (Figure 2), probably indicating disorder
and complete solvent exposure. P5 may interact withforms a hydrogen bond with the main-chain oxygen of
Thr-b77 (Figure 3A). Hydrogen bonds to the same b77 Qb70, which projects out of the binding site adjacent
to P5. The P5 side chain is positioned projecting out ofcarbonyl oxygen have been observed between P2 Thr
and Asn residues in two mouse I-Ek/peptide complexes the peptide-binding site of MHC class II molecules at
the same relative position as a P5 Tyr projects out of(Fremont et al., 1996). P2 Arg was also found frequently
in peptides that bind to DRB1*0101 and DRB1*1101, the MHC class I HLA-A2 binding site and into a pocket
formed by hypervariable loops on a bound TCR, in theother RA-associated alleles (Hammer et al., 1992, 1994).
The P3 Ala methyl group side chain is exposed to crystal structure of the ternary complex of A6-TCR/
HTLV-1 Tax peptide/HLA-A2 (Garboczi et al., 1996a,TCR contacts on a shelf-like pocket identical to those
observed in DR1 and DR3, which accommodate the 1996b).
The side chain of Ala at P6 is sequestered from solventmethylene groups of a solvent-exposed Lys in the DR1/
HA complex (Stern et al., 1994a) and Met in the DR3/ in a deep cleft (Figure 3A). Pocket 6 is deeper in DR4
than in DR1 because of the smaller side chain of b11,CLIP (Ghosh et al., 1995). In the DR4/CII complex, a
water molecule occupies the approximate position which is a valine in DR4 and a leucine in DR1. The side
chain of Ala at P7, however, is only partly buried in awhere the e-amino group of P3 Lys is bound in the DR1/
HA complex (Stern et al., 1994a) and is hydrogen bonded shallow pocket along the b chain helix (Figure 3A). A
Tyr at b30 makes this pocket smaller in DR4 than DR1,to the main-chain carboxylate group of Gly-a58. Poly-
morphism in the DR pocket that binds P4 has been which has a Ser as the b30 residue. The P8 Gly has only
a hydrogen as a side chain in CII (1168±1180), but itassociated with both RA and pemphigus vulgaris (re-
viewed by Wucherpfennig and Strominger, 1995). In the is positioned so that other residues at P8 can project
prominently into solvent.DRB1*0401/CII(1168±1180) complex the Asp side chain
of P4 is deep in the binding site (Figure 3A) and forms Gly at P9 is positioned above a small, primarily nonpo-
lar pocket that contains a bound water molecule. Leu-a salt-bridged hydrogen bond with the e-amino group
of Lys-b71 (Figure 4A). The latter residue, which is part cine at P10 and arginine at P11 extend into solution
Structure of an HLA-DR4/Collagen Peptide Complex
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from the end of the peptide-binding site. The electron
density in this region does not show the side chain
positions, indicating that they are probably disordered
(Figure 2).
The N-terminal peptide residues at positions P 22
(Gln) and P 21 (Tyr) form hydrogen bonds from the
peptide main chain to conserved atoms on the DR4
(Figure 3B). The P 21 Tyr side chain projects upward
out of the binding site (Figure 3A), but there isno electron
density for the side chain of P 22, suggesting that it is
disordered. Eleven water molecules that contact the
bound peptide and adjacent residues in the binding site
are included in the refined model. At the N-terminal end
of the binding site, one water molecule is hydrogen
bonded to the main-chain amide of the P 21 tyrosine,
while another one forms a bridge between the Tyr hy-
droxyl group and OE1 of Glu-a55, at the top of the
Figure 5. Comparison of DR1/HA, DR3/CLIP, and DR4/CII(1168±
binding cleft. Another water molecule bridges DR4 resi- 1180)
dues Asn-62 (ND2) and Gly-58 (main-chain O), and the Superposition of DR1/HA (yellow), DR3/CLIP (blue), and DR4/CII
main-chain amide of P3 is bonded to a water molecule. (1168±1180) (red) shows small structural differences in the a helix
OD1 of Asp at P4 also forms a contact with a tightly of the b1 domains.
bound water (Figure 4A). The carbonyl oxygen of P6 Ala
hydrogen-bonds with two closely placed water mole-
DR1 (compare Figure 4C to Figures 4A and 4B). Peptide-cules, one of which is bonded to a third water that does
binding (Hammer et al., 1995; Rammensee et al., 1995)not have direct contacts to protein or peptide atoms.
and site-directed mutation studies (Hammer et al., 1995)The amide groups of Gly P7 and P8 hydrogen-bond with
suggest that the electrostatic charge of b71 has a strongtwo water molecules, one of which bridges to OD1 of
influence on peptide-binding specificity. Peptides inAsn-a69.
which P4 is positively charged bind to the DR4 subtypesPeptide residues from P 22 to P8 are expected to
that are not associated with RA (DRB1*0402) 100±1000be covered by the footprint of a TCR, based on the
times better than to RA-associated subtypes (DRB1*0401,orientation and contact area seen in the class I/MHC/
DRB1*0404), presumably because of the charge com-peptide interface (Garcia et al., 1996; Garboczi et al.,
plementarity between a positive P4 and negative Glu at1996a). Peptide side chains at P 21, P2, and P5 project
b71 in the former case and charge repulsion betweenprominently toward the T cell, but P 22, P3, P4, P6, P7,
a positive P4 and positive Lys at b71 in the latter caseP8, and P9 are also exposed and therefore may be
(Hammer et al., 1995). Peptides in which P4 is negativelyrecognized as well.
charged, such as Asp P4 in DR4/CII (1168±1180), corre-
spondingly bind better to RA-associated subtypes with
a positively charged b71 (Figures 4A and 4B) than toRA Susceptibility Correlates with Electrostatic
Charge Differences in the P4 pockets the nonassociated subtypes with a negatively charged
b71 (Figure 4C) (Hammer et al., 1995). Substitution of b71of DRB1*0401 and DRB1*0402
A specific constellation of polymorphic residues on the to the oppositely charged residue in the DR4 subtypes
reverses these preferences (Hammer et al., 1995). Thea helix of the b chain adjacent to pocket 4, residues 67,
70, 71, and 74 (Figure 4), has been identified as creating observation in the DR4/CII(1168±1180) crystal structure
of a salt-linked hydrogen bond forming from b71 to thean epitope shared by DR allelic products associated
with RA (Silver and Goyert, 1985; Gregersen et al., 1987; negatively charged Asp at P4 is consistent with the ear-
lier suggestion (and molecular model) that the selectiveHiraiwa et al., 1990). In the DR4/CII(1168±1180) struc-
ture, Lys-b71 forms hydrogen bonds with both the main- binding of peptides by the P4pocket may be a major part
of the mechanism of MHC association to RA (Hammer etchain carbonyl oxygen of P5 and the Asp side chain of
P4 (Figure 4A), and Gln-b70 points out of the binding al., 1995).
The location of the b chain a helix in DR4/CII(1168±site toward the T cell. The main chain of the peptide is
also held in place by hydrogen bonds from Asn-62, a 1180) also differs from both DR1/HA and DR3/CLIP near
residues b65 and b74 (Figure 5). In the DR3-CLIP struc-conserved residue on the a helix across the binding
groove (top in Figure 4A). In pocket 4 of the DR1/HA ture, the peptide residue at position P4 is Ala, which
has a small side chain, leading to a slightly ªcollapsedºpeptide complex, an Arg at b71 makes the same interac-
tion as does the Lys in DR4 (Figure 4B), but Gln-b70 pocket with the a-helical residues moved closer to the
peptide (blue in Figure 5). An Asp side chain will not fitpoints down into the pocket to contact theP4 side chain.
The DRB1*0402 subtype, which is not associated with in the P4 pocket seen in DR3/CLIP structure, even
though Asp is the preferred P4 residue for DR3 (GhoshRA, has the acidic residues Asp and Glu at b70 and b71
(modeled in Figure 4C). The Glu at b71 in DRB1*0402 et al., 1995). In the DR4/CII (1168±1180) structure,pocket
4 accommodates the larger Asp side chain at P4 by alacks a hydrogen bond donor and therefore would not
be able to form a hydrogen bond to the main-chain car- relative expansion of the pocket (red in Figure 5). Simi-
larly, the P4 pocket in DR1/HA is larger (yellow in Figurebonyl oxygen of P5 as did the Lys and Arg on DR4 and
Immunity
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5), but the helical region between residues b65 and b74 model. P6 Gly replaces Ala of CII(1168±1180). P7 Pro
fits in the shallow pocket 7, but Tyr-30 or P7 may moveis not exactly superimposable on the corresponding one
in DR4/CII (1.0 AÊ root-mean-square deviation). These slightly in the real structure, as the fit is tight. P9 is Gly
in both CII peptides. The side chains at P 21 and P3,observations suggest that the exact positioning of this
helix may vary according to the peptide side chain occu- expected to extend into solution, are only the hydrogens
of Gly residues, so that TCRs could fit very tightly topying the P4 pocket.
the MHC molecule at these positions. In contrast, P5
Gln and P8 Lys are expected, by analogy to previous
The Dominant Peptide Epitope in Collagen-Induced peptides (Figure 6B), to extend prominently into solution
Arthritis of DR1 and DR4 Transgenic Mice and be contacted by TCRs. Although the DR4/CII(261±
(CII(261±273)) Can Be Modeled from 273) complex is only a hypothetical model, the analogy
the DR4/CII(1168±1180) Structure to CII(1168±1180) is so close and the mode of peptide
Although the responsible antigen and the mechanism binding to MHC class II molecules so conserved, that
of DR linkage to increased susceptibility to RA is un- the model is probably accurate enough for the planning
known in humans (e.g., Zanelli et al., 1995, 1996), there of experiments. The differences between the model and
is evidence of both humoral and cellular responses to the actual structure are probably less than the differ-
collagen II, which is a major component of joint cartilage ences in peptide structure between the Tax 9-mer pep-
(Stuart et al., 1983; Jasin, 1985; Watson et al., 1986; tide bound to HLA-A2 and the same peptide in the TCR/
Londei et al., 1989; Terato et al., 1990). Transgenic mice Tax/HLA-A2 crystal structure, where rearrangements of
expressing human DRB1*0401 and the human corecep- two peptide residues of up to 4AÊ were observed follow-
tor CD4 (Fugger et al., 1994, 1996) as well as mice trans- ing TCR binding (Garboczi et al., 1996a).
genic for chimeric DRB1*0101 (Rosloniec et al., 1997)
harboring the DR1 peptide-binding site and mouse se- Experimental Procedures
quences in the class II MHC membrane-proximal CD4-
Expressioninteracting domains have been shown to generate a T
The expression vectors for soluble DR4 were made by reverse tran-cell response to immunization by CII. The same core
scription±polymerase chain reaction (PCR) of mRNA isolated fromCII peptide sequence (CII(263±270)) is immunodominant
the DRB1*0401-expressing EB virus-transformed B cell line, Priess.
(Fugger et al., 1996; Rosloniec et al., 1997) in both The PCR primers amplified sequences encoding amino acids 1±217
transgenic mouse models. of the a chain and 1±227 of the b chain. The PCR products were
We have modeled the CII(261±273) peptide (AGFK- subcloned into the EcoRI/BamHI sites of the pRmHA-3 expression
vector (Bunch et al., 1988). Stable transformants of Drosophila S2GEQGPKGEP, P1 5 F), which is recognized by the ma-
cells were generated by cotransformation with pUChsneo (Stellarjority of CII reactive HLA-DRB1*0401±restricted T cells
and Pirrotta, 1985) and selection with G418. High-secreting singlefrom the DR4 transgenic mouse model (Fugger et al.,
cell±derived clones were isolated by limiting dilution culture. Cells
1996) (Figure 6A) by analogy to the DR4/CII (1168±1180) were grown in spinner flasks in ExCell 401 medium (Sigma) supple-
structure (Figure 3A). The modeling is facilitated by the mented with 1% fetal bovine serum (Sigma) to a density of 5 3 106
observation that the five peptides in the MHC class II cells/ml, after which expression was induced by addition of 1 mM
CuSO4. Cells were allowed to incubate for another 6 days beforestructures determined to date, which include DR1, DR3,
harvesting, after which they were centrifuged at 48C for cellularDR4, and I-Ek, have remarkably similar conformations
debris removal.(Figure 6B) (Stern et al., 1994a; Ghosh et al., 1995; Fre-
mont et al., 1996; Jardetzky et al., 1996). In every case,
Purification and Crystallization
P1, P4, P6, P7, and P9 are at least partially buried in Recombinant DR4 was purified by immunoaffinity chromatography;
pockets, while P 22, P 21, P2, P3, P5, P8, P10, and specifically, the supernatant from the harvested cells was loaded
P11 are substantially exposed to solvent, with the side onto a Protein A column and subsequently onto a monoclonal anti-
body LB3.1 column. Bound protein was eluted with 50 mM CAPSchains at P 21, P5, and P8 projecting directly up away
(pH 11.5) and neutralized with 200 mM phosphate (pH 6.0). Bindingfrom the MHC molecule surface (Figure 6B). As dis-
of peptide QYMRADQAAGGLR (CII 1168±1180) to the eluted HLA-cussed earlier (Stern et al., 1994a; Jardetzky et al., 1996),
DR4 was performed at 378C for 48 hr in the presence of 5% glycerol.
the peptide main- chain conformations are regular and After incubation, the DR4-peptide complex was purified by gel filtra-
similar to those of polyproline type II. The main chains tion chromatography using a Superdex 200 column in 50 mM Tris-
overlap almost perfectly from P 22 to P5 (Figure 6B), Cl (pH 8.0) 1 0.1 M NaCl; the eluted peak was exchanged into 25
mM Tris-Cl (pH 8.0) buffer and concentrated to 8 mg/ml in Centricondiverging after that as some of the peptides fit 1.0±2.0
10 concentrators (Amicon). SEB (Sigma; suspended in the latterAÊ deeper into the binding site from P6 to P10 (Ghosh
buffer) was added in a 1.5:1 molar ratio prior to crystallization. Crys-et al., 1995).
tals of the DR4-CII(1168±1180)/SEB complex were obtained at 258C
The CII(261±273) peptide is expected to align with in 0.1 M sodium acetate (pH 4.6), 9%±14% polyethylene glycol (PEG)
Phe-263 (P1) bound in the large nonpolar pocket 1, 4K, 0.2 M ammonium acetate, as well as in 0.1 M glycine (pH 3.85),
which was occupied by Met in the DR4/CII(1168±1180) 9%±14% PEG 4K, 0.1 M ammonium sulfate. Crystals appeared in
2 days and grew to dimensions of 0.5 3 0.5 3 0.2 mm.complex, with Glu-266 (P4) positioned in pocket 4 to
form a salt-bridged hydrogen bond to Lys-b71 as does
Data Collection and ProcessingP4 Asp in CII(1168±1170) (compare Figure 6A to Figure
Data were collected at the Cornell High Energy Synchrotron Source3A) (Fugger et al., 1996). In addition, the Lys at position
(CHESS) using a CCD detection system (l 5 0.91 AÊ ). A crystal grownP2 could be hydrogen bonding to the main chain of
in the sodium acetate condition was introduced into a solution of
Thr-b77, as is Arg at P2 in the CII(1168±1180) peptide 0.1 M ammonium sulfate, 15% PEG 4K, and 25% glycerol prior to
(Figures 6A and 3A). All of the peptide main- chain hydro- mounting and flash-cooling; 1.08 oscillation frames were collected,
and all data were indexed and integrated using DENZO (Otwinowski,gen bonds to DR4 (Figure 3B) can be maintained in the
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Figure 6. Conformations of Peptides in the
Binding Sites of MHC Class II Molecules
(A) Hypothetical model of CII(261±273) pep-
tide in the HLA-DR4 binding cleft. Phe-263
fits into the P1 pocket, and Glu (P4) hydrogen
bonds to b71.
(B) The conformations of five peptides ob-
served in complexes with human and murine
class II MHC molecules: DR1/HA (green),
DR3/CLIP (purple), DR4/CII(1168±1180) (yel-
low), Iek/HB (red), and Iek/HSP70 (blue). The
MHC class II molecules were superimposed
to reveal the superposition of the peptides.
View is approximately with MHC to the left
and TCR to the right.
1993) and scaled using SCALEPACK (CCP4). Data collected at and translation (12±3.0 AÊ ) procedures, the top solution (Rcryst 42%)
was 9 s higher than the next solution. The asymmetric unit of theCHESS are 87.7% complete to a resolution of 2.5 AÊ . The DR4-
CII(1168±1180)-SEB complex crystallizes in orthorhombic space crystal contains a single ab heterodimer complexed to a single
SEB molecule; neither of the HLA class II heterodimers observedgroup P212121, with unit cell parameters a 5 78.52 AÊ , b 5 100.28 AÊ ,
c 5 100.86 AÊ , and a 5 b 5 g 5 908. previously (Brown et al., 1993; Jardetzky et al., 1994; Stern et al.,
1994a; Ghosh et al., 1995; Fremont et al., 1996) was identified in
this lattice.Molecular Replacement
A molecular replacement solution was identified with XPLOR
(BruÈnger, 1992) using the DR1/SEB complex (Jardetzky et al., 1994) Model Building and Refinement
A random 10% of reflections were omitted from refinement for aas a search model, for which 16 residues differing between DR1
and DR4 were substituted by Ala. After cross-rotation (12±3.0 AÊ ) calculation of Rfree (BruÈnger, 1992) prior to refinement. To improve
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